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ABSTRACT 
Breast cancer risks conferred by many germline missense variants in the BRCA1 and BRCA2 
genes, often referred to as variants of uncertain significance (VUS), have not been established. 
In this study, associations between 19 BRCA1 and 33 BRCA2 missense substitution variants 
and breast cancer risk were investigated through a breast cancer case control study using 
genotyping data from 38 studies of predominantly European ancestry (41,890 cases and 41,607 
controls) and nine studies of Asian ancestry (6,269 cases and 6,624 controls). The BRCA2 
c.9104A>C, p.Tyr3035Ser (OR=2.52, p=0.04) and BRCA1 c.5096G>A, p.Arg1699Gln 
(OR=4.29, p=0.009) variant were associated with moderately increased risks of breast cancer 
among Europeans, whereas BRCA2 c.7522G>A, p.Gly2508Ser (OR=2.68, p=0.004) and 
c.8187G>T, p.Lys2729Asn (OR=1.4, p=0.004) were associated with moderate and low risks of 
breast cancer among Asians. Functional characterization of the BRCA2 variants using four 
quantitative assays showed reduced BRCA2 activity for p.Tyr3035Ser compared to wildtype. 
Overall, our results show how BRCA2 missense variants that influence protein function can 
confer clinically relevant, moderately increased risks of breast cancer, with potential implications 
for risk management guidelines in women with these specific variants.  
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INTRODUCTION 
Mutation screening of the BRCA1 and BRCA2 genes has resulted in the discovery of thousands 
of unique germline BRCA1 and BRCA2 variants. Many pathogenic variants of BRCA1 or 
BRCA2 resulting in truncation of these proteins, along with a small number of pathogenic 
missense variants, have been associated with high risks of breast cancer with cumulative risks 
of 55% to 85% by age 70 (1). In contrast, the influence on cancer risk of many rare variants of 
uncertain significance (VUS), accounting for between 2% and 10% of results from genetic 
testing, is not known (2-4). As a result, carriers of VUS in these predisposition genes cannot 
benefit from cancer risk management strategies for women with pathogenic mutations.  
 
Clinical classification of BRCA1 and BRCA2 VUS has been largely based on probability-based 
models which incorporate likelihood-ratios associated with family history of cancer, co-
segregation of variants with breast and ovarian cancer within families, tumor histopathology, 
and prior probabilities of pathogenicity associated with cross-species amino acid sequence 
conservation (5, 6). While over 200 BRCA1 and BRCA2 variants have been classified as 
pathogenic or neutral/non-pathogenic using a multifactorial likelihood model (7-10) , many VUS 
remain because of limited availability of families segregating the variants. Clinical classification 
of VUS in BRCA1 and BRCA2 has been further complicated by the identification of variants with 
partial effects on protein function (5, 11, 12). However, to date only the BRCA1 c.5096G>A, 
p.Arg1699Gln (R1699Q) variant has been associated with a reduced cumulative risk of breast 
cancer (24% by age 70) (13). R1699Q has also been associated with lower penetrance relative 
to the pathogenic c.5095C>T, p.Arg1699Trp (R1699W) variant in the same residue. In this 
study, the influence of 52 missense variants in BRCA1 and BRCA2 on breast cancer risk was 
investigated using the iCOGS breast cancer case-control project (14). In addition, the impact of 
the BRCA2 c.9104A>C, p.Tyr3035Ser (Y3035S), c.7522G>A, p.Gly2508Ser (G2508S), and 
c.8187G>T, p.Lys2729Asn (K2729N) variants on BRCA2 function were evaluated relative to 
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known pathogenic and neutral variants using biochemical, cell-based homology directed repair 
(HDR), and in vivo embryonic stem (ES) cell-based assays. The combination of these genetic 
and functional studies show that missense variants in the DNA binding domain of BRCA2 with 
partial effects on protein function can confer moderate risks of breast cancer. 
 
MATERIALS AND METHODS 
Participants 
Breast cancer cases and controls from 38 studies of predominantly European ancestry (41,890 
cases with invasive disease and 41,607 controls) and nine studies of Asian ancestry (6,269 
cases and 6,624 controls) from the Breast Cancer Association Consortium (BCAC) were used 
for genotyping (Supplementary Table S1). All studies were approved by local ethics committees 
and institutional review boards. 
 
Variant selection 
Missense substitution variants from BRCA1 (n=19) and BRCA2 (n=33) were selected by 
ENIGMA for inclusion on the iCOGS genotyping array based on frequency in the ENIGMA 
database (15) (Supplementary Tables S2). Variants are defined by Human Genome Variant 
Society (HGVS) nomenclature and are based of Refseq transcripts (BRCA1: NM_007294.3 ; 
BRCA2: NM_000059.3). 
 
Genotyping 
Genotyping was conducted using the custom Illumina Infinium array (iCOGS) (14). DNA 
samples containing each of the variants were included in iCOGS genotyping as positive controls 
and were used to inform genotype calling. Genotypes were called with the GenCall algorithm. 
Descriptions of sample and genotype quality control have been published (14, 16). Cluster plots 
for rare variants for this study were manually evaluated relative to positive control samples. 
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Statistical Methods  
Case-control analysis - The association of each variant with breast cancer risk was assessed 
using unconditional logistic regression, adjusting for study (categorical). Analyses were 
restricted to either Caucasian or Asian women. Cases selected for iCOGS based on personal or 
family history of breast cancer were excluded to obtain unbiased OR estimates for the general 
population. The significance of associations (P-values) was determined by the likelihood ratio 
test comparing models with and without carrier status as a covariate. Because this study was 
focused on estimating breast cancer risk associated with each variant, analyses were not 
adjusted for multiple testing. Moderate risk of breast cancer was defined as odds ratio (OR) 
from 2.0 to 5.0 and high risk of breast cancer was defined as OR>5.0. 
 
Segregation analysis - Risks of breast cancer were assessed using pedigrees based on the 
likelihood of the observed pedigree genotypes conditional on the pedigree phenotypes and the 
genotype of the index case. The primary analysis calculated the penetrance for breast cancer in 
carriers of the p.Y3035S variant assuming a constant relative risk with age. A second analysis 
allowed for a similar pattern of age specific effects as for population based pathogenic BRCA2 
variants and calculated the optimal cumulative penetrance at 75% of pathogenic BRCA2 
variants. The age-specific hazard ratio (HR), by decade, was assumed to be a constant multiple 
of the population based estimates for BRCA2 pathogenic mutations, with cumulative penetrance 
re-estimated at each trial value of the multiplier. This provided for a similar pattern of age-
specific effects as in BRCA2, but allowed testing of different penetrance values and only 
required estimation of a single parameter. Models were fitted under maximum likelihood theory 
using a modified version of the LINKAGE genetic analysis package (17). Non-carriers were 
assumed to be at population risks with incidence rates taken from cancer registry data obtained 
from Cancer Incidence in Five Continents, VIII (IARC, Lyon) and risk ratios (RR, the age specific 
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breast cancer incidence rate in carriers divided by the relevant population rate) were estimated. 
Reported breast cancers with unknown age at diagnosis were excluded from all analyses. 
Cancers other than breast (including ovarian cancer) were treated as unaffected at the age of 
their cancer diagnosis. 
 
Cell Lines 
V-C8 cells were a kind gift from Dr. M.Z. Zdzienicka. 293T cells were obtained from ATCC 
(CRL-3216). Cells were authenticated by short tandem repeat analysis using the kit 
GenePrint10 kit (Promega). All the cell lines used in this study were routinely checked for 
mycoplasma contamination using the MycoProbe Mycoplasma Detection Set (R&D Systems). 
Cells were limited to 6 weeks in culture.  
 
Homology directed repair (HDR) assay 
The HDR assay for evaluating the influence of variants in the BRCA2 DNA binding domain 
(DBD) on BRCA2 homologous recombination DNA repair activity has been described previously 
(11). Full-length human BRCA2 wild-type and mutant cDNA expression constructs were co-
expressed with an I-Sce1 expressing plasmid in Brca2 deficient V-C8 cells, stably expressing 
the DR-GFP reporter plasmid. Homologous recombination-dependent repair of I-Sce1 induced 
DNA double strand breaks were quantified by fluorescence-activated cell sorting (FACS) of GFP 
positive cells after 72 hours. Two independent clones of each variant were evaluated in the 
HDR assay on three separate occasions. Equivalent expression of wild-type and mutant BRCA2 
proteins was confirmed by western blot analysis of anti-Flag-M2 (Sigma F1804) antibody 
immunoprecipitates from V-C8 cell lysates.  
 
Purification of full-length wild-type and mutated BRCA2 protein  
Wild-type and mutant human BRCA2 cDNAs were cloned into the C-terminal MBP-GFP-tagged 
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phCMV1 expression plasmids and purified as described (18, 19). Briefly, 10 x 15-cm plates of 
HEK293 cells were transiently transfected using TurboFect (Thermo Scientific) following the 
manufacturer specifications and harvested 30 hours post-transfection. Cell extracts were bound 
to Amylose resin (NEB), and the protein was eluted with 10 mM maltose. The eluate was further 
purified by ion exchange using BioRex 70 resin (BIO-RAD) and step eluted at 250mM, 450 mM, 
and 1M NaCl (18, 19). Each fraction was tested for nuclease contamination. The 1M NaCl 
fractions were used for the DNA binding assay because they were free of nuclease 
contamination. 
 
Electrophoretic Mobility Shift Assay (EMSA) 
The ssDNA substrate (oAC423) used for DNA binding was obtained from Sigma and purified by 
polyacrylamide gel electrophoresis (PAGE). Purified wildtype or mutated BRCA2 at 
concentrations 0, 1, 5, 10, 20 nM was mixed with the ssDNA oligonucleotide oAC423 167-mer 
(0.2 µM nt), labeled with 32P at the 5’ end, in a buffer containing 25 mM TrisAcO (pH 7.5), 1 mM 
MgCl2, 2 mM CaCl2, 1mM DTT, 1 mM ATP, 100 µg/ml BSA, and incubated for 60 min at 37°C. 
Reaction products were resolved by 6% PAGE, imaged on a Typhoon PhosphorImager 
(Amersham Biosciences), and analyzed with Image Quant software. The relative amount of 
product was calculated as labeled complex divided by the total labeled input DNA in each lane. 
The protein-free lane defined the value of 0% complex.  
oAC423: 5'-CTGCTTTATCAAGATAATTTTTCGACTCATCAGAAATATCCGTTTCCTATATTT 
ATTCCTATTATGTTTTATTCATTTACTTATTCTTTATGTTCATTTTTTATATCCTTTACTTTATTT
TCTCTGTTTATTCATTTACTTATTTTGTATTATCCTTATCTTATTTA-3'. 
 
Embryonic Stem (ES) cell complementation 
Selected BRCA2 variants were functionally analyzed based on the ability of human BRCA2 to 
complement the lethality of mouse Brca2 deficiency (20, 21). BRCA2 exons containing VUS 
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were generated by mutagenesis PCR and engineered into a human BRCA2 (hBRCA2) Bacterial 
Artificial Chromosome (BAC) by Red/ET BAC recombineering in DH10B E.coli. BAC DNA was 
transfected into mES cells containing a conditional mouse Brca2 allele and a disrupted Brca2 
allele (Brca2-/loxP), and the DR-GFP construct integrated at the pim1 locus. hBRCA2 containing 
cells were selected by G418. Per variant, two independent BAC transfections were performed 
and G418-resistant clones from each BAC transfection were pooled. Cell pools were transfected 
with Cre-recombinase expression construct to remove the conditional mBrca2 gene. hBRCA2 
RNA and protein expression were confirmed by quantitative RT-PCR and western blotting, 
respectively. 
 
ES cell functional assays 
After Cre-recombinase transfection, mBrca2 depleted cells were selected for restoration of the 
HPRT minigene using hypoxanthine-aminopterin-thymidine (HAT) containing medium. HAT 
resistant clones were pooled and evaluated for BRCA2 activity using functional assays. In the 
mES cell HDR assay, cells were transfected with an I-Sce1 expression vector, pCMV-RED-
ISce, and GFP positive cells were quantified by flow cytometry 48 hr after transfection. mES 
cells were also treated with varying doses of PARP inhibitor (KU-0058948, Astra Zeneca) and 
viable cells were quantified after 48 hr. Cell survival was calculated as the fraction of treated 
surviving mES cells relative to the cell count of untreated surviving cells per cell line. 
 
RESULTS 
Association of BRCA1 and BRCA2 variants with breast cancer risk 
A total of 19 BRCA1 and 33 BRCA2 variants encoding missense substitutions and the known 
pathogenic BRCA1 protein truncating variant c.4327C>T, p.Arg1443Ter (R1443X) were 
genotyped for 48,159 breast cases and 48,231 controls from the Breast Cancer Association 
Consortium (BCAC) on the iCOGS custom genotyping array (Supplementary Table S1). Among 
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the BRCA1 variants, 12 have been classified as Class 1-neutral, 6 as Class 3-uncertain, and 2 
as Class 5-pathogenic, by the quantitative multifactorial likelihood model that the ENIGMA 
consortium (www.enigmaconsortium.org) uses for expert panel review of BRCA1 and BRCA2 
variants for ClinVar (http://www.ncbi.nlm.nih.gov/clinvar) and BRCA Exchange 
(http://brcaexchange.org)  (Supplementary Table S2). Among the Class 3 variants, BRCA1 
c.5207T>C, p.Val1736Ala (V1736A) is known to disrupt BRCA1 activity (22), and both V1736A 
and c.5363G>A, p.Gly1788Asp (G1788D) are annotated as pathogenic by multiple sources in 
the ClinVar database. Among the BRCA2 variants, 25 have been classified as Class 1-neutral 
or Class 2-likely neutral, 6 are Class 3-uncertain, and two (c.8167G>C, p.Asp2723His 
(D2723H); c.9154C>T, p.Arg3052Trp (R3052W)) have been classified as Class 5-pathogenic 
using the same multifactorial likelihood model (Supplementary Table S2). Among these, 18 are 
located in the DNA binding domain (amino acids 2460-3170). 
 
The BRCA1 R1443X truncating pathogenic variant was associated with high risk of breast 
cancer (odds ratio (OR) = 8.3, p=0.045) in the Caucasian case-control analysis in iCOGS (Table 
1 and Supplementary Table S3), consistent with what has been estimated for truncating 
pathogenic BRCA1 variants. Among the missense variants, c.5096G>A, p.Arg1699Gln 
(R1699Q) was associated with a moderate risk of breast cancer (OR=4.29, p=0.009) (Table 1 
and Supplementary Table S3). This result was lower than expected for pathogenic BRCA1 
variants, but consistent with the moderate penetrance of this variant estimated from family-
based studies (13). Several BRCA1 variants including the known pathogenic c.5123C>A, 
p.Ala1708Glu (A1708E); the c.5207T>C, p.Val1736Ala (V1736A); and c.5363G>A, 
p.Gly1788Asp (G1788D) variants that are identified as pathogenic in ClinVar were not observed 
in sufficient numbers of cases and controls to allow for estimation of breast cancer risks 
(Supplementary Tables S2 and S3). Three BRCA2 variants were statistically significantly 
associated with increased breast cancer risk (p<0.05) for Caucasian or Asian women. BRCA2 
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c.7522G>A, p.Gly2508Ser (G2508S) was observed in 31 cases and 12 controls in the Asian 
studies (OR=2.68, p=0.004) but not in any Caucasians, BRCA2 c.8187G>T, p.Lys2729Asn 
(K2729N) was observed in 164 cases and 128 controls in the Asian studies (OR=1.41, 
p=0.004), and BRCA2 c.9104A>C, p.Tyr3035Ser (Y3035S) was observed in 18 cases and 7 
controls in the Caucasian studies (OR=2.52, p=0.038) (Table 1 and Supplementary Table S3).  
In addition, the BRCA2 c.4258G>T, p.Asp1420Tyr (D1420Y) (OR=0.86, p=0.005) and 
c.8149G>T, p.Ala2717Ser (A2717S) (OR=0.77, p=0.02) were negatively associated with risk for 
Caucasian women (Table 1 and Supplementary Table S3). None of the remaining BRCA2 
variants, including the Class 5-pathogenic BRCA2 variants, c.8167G>C, p.Asp2723His 
(D2723H) and c.9154C>T, p.Arg3052Trp (R3052W), were observed in enough cases and 
controls for estimation of breast cancer risk (Supplementary Table S3). Thus, for the first time 
BRCA2 variants encoding missense alterations (G2508S, K2729N, and Y3035S) have been 
associated with moderately (OR<5.0) increased risks of breast cancer. 
 
To assess further the association with breast cancer for the BRCA2 G2508S and Y3035S 
potentially clinically relevant moderate risk variants, pedigrees for segregation analysis were 
collected through the ENIGMA consortium. Nineteen pedigrees with the Y3035S variant were 
collected (Fig. 1, Supplementary Fig. S1, Supplementary Table S4). Only one pedigree was 
obtained for G2508S suggesting this variant is rare in the Caucasian population. Segregation 
studies of Y3035S, assuming the relative risk was constant with age, indicated an association 
with breast cancer risk (Risk Ratio (RR)=14.8; 95%CI 2.4-20.0) (Supplementary Table S4). A 
second analysis, allowing for a similar pattern of age specific effects as for population-based 
pathogenic BRCA2 truncating variants, estimated the optimal cumulative penetrance for 
Y3035S at 0.75 of known pathogenic truncating BRCA2 variants, and yielded a similar risk ratio 
for breast cancer (Supplementary Table S4). Y3035S co-occurred with a pathogenic BRCA2 
variant (S1882X) in Pedigree G (Supplementary Fig. S1). Co-occurrence with S1298del in 
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Pedigree K  (Figure 1) was not informative because S1298del is a VUS. Together the case-
control study and the pedigree analysis suggest that Y3035S is associated with moderately 
increased breast cancer risk.  
 
Cell-based HDR analysis of BRCA2 variants 
Inactivation or depletion of BRCA2 has been associated with deficient homology directed repair 
(HDR) of DNA double strand breaks (23), which can be quantified with a cell-based HDR green 
fluorescent protein (GFP) reporter assay (24). This assay has shown 100% sensitivity and 
specificity for known pathogenic missense variants in the BRCA2 DNA-binding domain and has 
been used for characterization of BRCA2 VUS (8, 11, 25). In this study, the impact of the 
G2508S, A2717S, K2729N, and Y3035S missense variants on BRCA2 HDR activity was 
assessed relative to the D2723H and R3052W known pathogenic and the c.9292T>C 
p.Tyr3098His (Y3098H) known neutral BRCA2 variants (11, 26). D1420Y was not evaluated 
because the variant is not located in the BRCA2 DBD. All wildtype and mutant BRCA2 proteins 
displayed equivalent levels of expression relative to β-actin by western blot (Supplementary Fig. 
S2). The D2723H and R3052W Class 5 pathogenic variants (11) showed substantial loss of 
BRCA2 HDR activity (Fig. 2A and Table 2). In contrast, BRCA2 Y3035S showed intermediate 
levels (2.3-fold relative to D2723H) (Fig. 2A and Table 2) of BRCA2 HDR activity. This was 
outside the thresholds for known pathogenic and neutral missense variants (HDR fold-change 
<1.66 and >2.41, respectively, that equate to 99% probabilities of pathogenicity and 
neutrality(11). This intermediate functional effect was consistent with the moderate risk of breast 
cancer (OR=2.52, p=0.038) observed in the iCOGS case-control study (Table 1) and the 
estimated 0.75-fold penetrance of pathogenic BRCA2 variants from segregation studies 
(Supplementary Table S4). This is the first evidence that reduced BRCA2 function is associated 
with an intermediate or moderate risk of breast cancer.  
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In contrast, BRCA2 G2508S exhibited 3.2-fold HDR activity relative to D2723H (Fig. 2A and 
Table 2). While reduced relative to wildtype activity, this level of HDR activity was associated 
with >99% probability of neutrality. Similarly, BRCA2 K2729N showed reduced HDR activity 
relative to the wildtype protein (Fig. 2A and Table 2), which was consistent with a mild influence 
on breast cancer risk (OR=1.41, p=0.004) in the Asian population, and >99% probability of 
neutrality (Fig. 2A). Together these results show that the HDR assay is calibrated relative to 
levels of cancer risk, with minor functional effects for variants associated with low- or modest 
risks of breast cancer such as c.9976A>T, p.Lys3326Ter (K3326X) (OR=1.28) (27) and K2729N 
(OR=1.41), more substantial functional effects for the intermediate risk Y3035S (OR=2.52), and 
strong effects for known pathogenic variants such as D2723H and R3052W (Fig. 2A). Thus, the 
HDR assay may predict the level of risk associated with any BRCA2 DBD variant.  
 
Single strand DNA (ssDNA) binding activity of BRCA2 variants 
BRCA2 directly binds to ssDNA and recruits RAD51 to ssDNA at sites of DNA damage during 
homologous recombination DNA repair (18, 28). Hence, ssDNA binding is integral to the 
homologous recombination activity of BRCA2. On this basis, an in vitro biochemical assay was 
used to examine the influence of the BRCA2 variants on BRCA2 ssDNA binding activity. Full-
length wildtype and mutant human BRCA2 proteins tagged with (N-terminal) green fluorescence 
protein (GFP) and maltose-binding protein (MBP) (GFP-MBP-BRCA2) were expressed and 
purified to near homogeneity (Supplementary Fig. S3) as described previously (18, 19).  Full-
length BRCA2 protein expression was confirmed by western blotting using an antibody against 
the C-terminus of BRCA2 (Supplementary Fig. S3). The ssDNA binding activity of full-length 
wildtype and mutant BRCA2 proteins was evaluated using an electrophoretic mobility shift 
assay (EMSA). The wildtype protein bound to ssDNA with a yield of ~18% at the maximum 
attainable concentration of BRCA2 protein (Fig. 2B, 2C, and Table 2), consistent with previous 
results (18), whereas the R3052W pathogenic control exhibited 2-fold reduced protein-ssDNA 
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complex formation (~8%) (Fig. 2B, 2C, and Table 2). Likewise, the Y3035S variant exhibited 2-
fold reduced complex formation compared to the wildtype protein (Fig. 2B, 2C, and Table 2). In 
contrast, G2508S, A2717S, and K2729N showed only partially reduced (~12% to 13%) protein-
ssDNA complex formation (Fig. 2B, 2C, and Table 2). These findings are consistent with 
predictions from the crystal structure of the BRCA2 DBD, where Y3035S is predicted to impair 
DNA binding, similarly to R3052W, because of proximity to DNA in the ssDNA-BRCA2 complex 
(Supplementary Fig. S4) (26). Overall, the results suggest that the reduction in HDR activity 
observed for Y3035S (Fig. 2A) is due to a defective ssDNA binding activity. 
 
Mouse embryonic stem cell-based functional analysis of BRCA2 missense variants 
Functional complementation of murine (m) Brca2-null ES cell lethality by human (h) BRCA2 
variants (20, 21) has been used to characterize BRCA2 VUS. Wildtype human BRCA2 
expression rescues Brca2 deficient ES cells from lethality, whereas ES cells expressing known 
pathogenic forms of BRCA2 fail to survive (20). In addition, several variants have shown partial 
or reduced ES cell survival relative to wildtype BRCA2. Surviving cells expressing these variants 
have shown moderate defects in HDR assays and sensitivity to cisplatin or a PARP inhibitor 
(29). In this study two independent pools of BAC clones for each of hBRCA2 G2508S, A2717S, 
D2723H, K2729N, Y3035S, and R3052W were tested for complementation of mBrca2 
deficiency and HDR activity. Cells expressing hBRCA2 D2723H or R3052W pathogenic variants 
did not survive after disrupting endogenous mBrca2 expression and were not included in the 
downstream functional analysis. Instead, we included mES cells expressing the W31C variant 
as a negative control. This variant conferred a severe defect in HDR activity because of 
disruption of the BRCA2-PALB2 interaction (30). 
 
BRCA2 W31C, G2508S, A2717S, K2729N, and Y3035S BACs rescued the lethality of the 
mBrca2-deficient ES cells, suggesting at least partial functional complementation of mBrca2 
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deficiency. HDR activity of surviving cells was assessed using the DR-GFP reporter assay. 
BRCA2 W31C showed only 14% (p<0.001) activity, whereas BRCA2 Y3035S, G2508S, and 
K2729N variants displayed 50% (p=0.002), 55% (p=0.007), and 70% (p=0.02) of wildtype HDR 
activity, respectively (Fig. 3A and Table 2). In contrast, HDR activity in cells expressing A2717S 
was not significantly different to wildtype protein (Fig. 3A and Table 2). The sensitivity of 
wildtype and mutant BRCA2 expressing ES cells to PARP inhibitor (KU-0058948) was 
evaluated to determine whether the reduction in HDR associated with some of the variants was 
sufficient to confer sensitivity to PARP inhibitor. Sensitivity was evaluated by counting viable 
cells after 48 hours of exposure to different doses of drug. Wildtype BRCA2, G2508S, and 
A2717S did not show sensitivity to PARP inhibitor, whereas W31C expressing cells showed 
significant sensitivity (Fig. 3B and Table 2). K2729N and Y3035S resulted in partial rescue of 
ES cell sensitivity (Fig. 3B and Table 2). Collectively, the ES cell HDR activity of the variants 
showed high concordance with the ORs from the case-control study, with Y3035S displaying 
partially deficient BRCA2 activity. In contrast, the level of HDR activity did not correlate well with 
different levels of PARP inhibitor sensitivity, although Y3035S was partially sensitive to PARP 
inhibitor, consistent with the results from other assays.  
 
DISCUSSION 
In this study, associations between 52 BRCA1 and BRCA2 missense variants and breast 
cancer risk were evaluated using a large breast cancer case-control study. To our knowledge, 
this is the largest case-control study conducted to establish the clinical relevance and estimate 
the risks of individual rare BRCA1 and BRCA2 variants encoding missense substitutions. The 
case-control analysis showed that BRCA1 c.5096G>A, R1699Q (OR=4.29) and BRCA2 
c.9104A>C, Y3035S (OR=2.52) were associated with moderately increased breast cancer risks 
for Caucasian women (Table 1), whereas BRCA2 c.7522G>A, G2508S (OR=2.68) and 
c.8187G>T, K2729N (OR=1.41) were associated with increased risks for Asian women. This is 
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the first study to estimate low to moderate risks of breast cancer for specific BRCA1 and BRCA2 
missense variants.  
 
The moderate risk of breast cancer associated with the BRCA1 R1699Q variant (OR=4.29) was 
consistent with previous findings from segregation analyses of breast cancer families, which 
estimated that R1699Q was associated with a cumulative risk of breast or ovarian cancer by 
age 70 years of 24% relative to the pathogenic R1699W variant and BRCA1 truncating variants 
(13). Similarly the quantitative ENIGMA multifactorial likelihood prediction model based on 
family data and sequence conservation yielded a posterior probability of pathogenicity for 
R1699Q of only 0.79 (13). Consistent with these findings, BRCA1 R1699Q protein has shown 
only partial protein function in HDR and other in vitro experiments (12, 13). Thus, the case-
control study and functional studies are consistent in identifying R1699Q as a moderate risk 
variant in BRCA1. 
 
BRCA2 Y3035S was associated with increased risk of disease (OR=2.52) for Caucasian 
women. While the numbers of cases and controls with the Y3035S variant were small, the 
moderate risk estimate is supported by family data showing partial co-segregation with breast 
cancer, and one pedigree in which BRCA2 Y3035S co-occurred with BRCA2 c.5645C>A 
p.Ser1882Ter (S1882X) (Supplementary Fig. S1). Several sequence-based in silico prediction 
models including MetaLR, MetaSVM, Vest3, and A-GVGD (prior probability of pathogenicity of 
0.66) (Supplemental Table S2) predicted Y3035S as deleterious. In addition, the missense 
substitution is predicted as likely deleterious by a protein likelihood ratio model based on 
sequence analysis (31). Analyses of splicing defects using Minigene-based assays have shown 
no influence on RNA splicing (32), suggesting that the increased risks are not due to abnormal 
splicing. Importantly, functional analysis of Y3035S using multiple independent assays 
consistently revealed partial activity. Y3035S showed intermediate BRCA2 HDR activity in VC8 
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cells, failed to restore HDR activity in ES cells (Fig. 3A), and only partially rescued sensitivity to 
PARP inhibition in ES cells (Fig. 3B). Similarly, Y3035S showed significantly reduced ssDNA 
complex formation (Fig. 2B and 2C) consistent with the location of Y3035 in the crystal structure 
of the BRCA2 DBD (28) (Supplementary Fig. S4). Together the functional studies indicate that 
Y3035S is a hypomorphic BRCA2 variant. Overall the case-control association study and 
functional analyses provide the first evidence that a hypomorphic BRCA2 missense variant can 
confer a moderate risk of breast cancer. However, Y3035S is consistently reported as “likely 
benign” and “benign” in the ClinVar public database. Since this database is widely used by 
researchers and clinicians, this under-appreciation of moderate risks of breast cancer 
associated with this variant has the potential to impact patient care. Further prospective studies 
are required to estimate age-dependent risks of cancer and to inform management protocols for 
carriers of this and other hypomorphic BRCA2 variants. 
 
The BRCA2 G2508S (OR=2.68, p=0.004) variant was associated with a moderate risk of breast 
cancer in Asian women, but could not be evaluated in the Caucasian population (Table 1). The 
variant was predicted neutral by a protein likelihood prediction model (31), but was predicted 
deleterious by other in silico prediction models including MetaLR, MetaSVM, Vest3, and A-
GVGD (prior probability of pathogenicity of 0.66) (Supplementary Table S2). However, the HDR 
V-C8 cell-based assay showed only mildly reduced activity similar to K2729N (OR=1.41) and 
p.K3326X (OR=1.28) (27), which are both classified as neutral (Fig. 2A). Likewise, the impact of 
G2508S on ssDNA binding was limited and most similar to K2729N (Fig. 2B, 2C). Although 
G2508S only partially rescued HDR activity in ES cells (Fig. 3A), the variant completely rescued 
sensitivity to PARP inhibition in ES cells similar to wildtype BRCA2 (Fig. 3B). Thus, the 
functional results suggest a limited impact on BRCA2 activity. As the variant has only been 
detected in the East Asian population (33, 34), one possibility is that genetic and environmental 
modifiers in the Asian population account in part for the influence of the variant on breast cancer 
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risk and the discrepancy between the case-control and functional study results. Further studies 
are needed to resolve this issue, but for now the breast cancer risks associated with this variant 
must be treated with caution. BRCA2 K2729N (OR=1.41, p=0.004) is also common in Asians, 
but rare in Caucasians (34). This variant has previously been classified as neutral by the 
multifactorial likelihood classification model (8). Consistent with these findings, functional 
analysis of K2729N showed only a minor influence on HDR function (8, 11) (Fig. 2A) and 
ssDNA binding (Fig. 2B), and substantial rescue of ES cell-based HR (Fig. 3A) and ES cell drug 
sensitivity (Fig. 3B). The mild defect in HR function correlated well with the low risk of breast 
cancer (OR=1.41, P=0.004) associated with the K2729N variant in the Asian case-control study.  
 
This study contains the first evidence that a biochemical assay using purified full-length BRCA2 
protein can be used to assess the DNA binding capacity of missense variants in the BRCA2 
DBD. While purification of wildtype full-length BRCA2 protein to near homogeneity has 
previously been described (18, 19), in this study the functional integrity of purified mutant 
BRCA2 proteins was assessed for the first time in a quantitative ssDNA binding assay. Full-
length proteins were used to limit potentially inaccurate interpretation of effects from partial 
protein fragments. The correlation of the ssDNA binding assay and HDR activity and the 
structural inspection of the DNA binding domain suggest that the reduction in HDR activity may 
result from a defect in ssDNA binding. The study also showed that the influence of BRCA2 
variants on HDR activity does not fully predict the response to PARP inhibitor in ES cells (Fig. 
3A and 3B). These findings suggest that only large reductions in HDR activity (<50%) will result 
in PARP inhibitor sensitivity. Whether tumors associated with these missense variants are 
sensitive to PARP inhibitor remains to be determined. 
 
Many unique missense variants and VUS in BRCA1 and BRCA2 have been reported in the 
Clinvar database but no validated high throughput methods for clinical classification of missense 
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variants in these genes have been established. Current methods of classification rely heavily on 
family data. This study highlights the potential for incorporating results from functional assays in 
the variant classification process, especially when family data is scarce. In particular, evaluation 
of missense variants in the BRCA2 DBD is possible with the cell-based HDR assay (11). 
Importantly, HDR results for variants with low or moderate levels of risk [K3326X (OR=1.28) 
(27), K2729N (OR=1.41), Y3035S (OR=2.52)], suggest that the HDR assay can be calibrated to 
differentiate between variants with high, moderate, or low breast cancer risks (Fig. 2A). 
Additional studies that combine the HDR assay data with family-based and sequence based 
models may result in classification of certain BRCA2 VUS as moderate breast cancer risk 
missense variants. ES cell complementation assays have also been used to identify inactivating 
missense variants in the BRCA2 DBD (14, 20, 29, 35), although the assay needs to be validated 
relative to known pathogenic and neutral BRCA2 variants before the results can be incorporated 
into VUS classification models.  
 
In summary, this study establishes for the first time the existence of BRCA2 missense variants 
that are associated with moderate risks of breast cancer.  Only through the very large iCOGS 
case-control association study was it possible to define the BRCA2 missense variant (Y3035S) 
as a moderate risk pathogenic variant for breast cancer (OR=2.52, p=0.038). Functional studies 
showed consistent partial or hypomorphic activity associated with Y3035S, suggesting that 
other BRCA2 variants with partial protein activity should be evaluated for moderate risks of 
breast cancer. Given that the age-related and lifetime risks of breast and ovarian cancer 
associated with moderate risk variants are likely to be substantially lower than for known 
pathogenic missense and truncating BRCA2 variants, risk management guidelines for 
individuals with these mutations may need to be redefined. Because Y3035S appears to confer 
similar risks of breast cancer as CHEK2 or ATM inactivating mutations, perhaps individuals 
carrying Y3035S or other moderate risk BRCA2 variants may benefit from following 
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management guidelines similar to individuals with CHEK2 and ATM variants rather than 
individuals with high-risk pathogenic BRCA2 variants. However, further studies are needed to 
establish accurate risks of cancer associated with hypomorphic, moderate risk BRCA2 variants 
before any modifications are considered. Ongoing efforts are focused on estimating cancer risks 
associated with additional selected hypomorphic/intermediate function variants through 
segregation studies in families, with the goal of calibrating the functional results with levels of 
cancer risk. 
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Table 1.  Variants in BRCA1 and BRCA2 significantly associated with breast cancer risk in a case-control analysis 
Sequence Variantsa Caucasian Asian 
Gene HGVS DNA HGVS Protein 
Protein 
change 
Case
n=41,890 
Control
n=41,607 ORb 95% CI 
P-
value 
Case
n=6,629 
Control
n=6,624 ORc 95% CI 
P-
value 
 c.2521C>T p.Arg841Trp R841W 160 207 0.81 0.66-1.00 0.045 1 0 - - - 
BRCA1 c.4327C>T p.Arg1443Ter R1443X 9 1 8.3 1.05- 16.0 0.045 1 1 1.5 0.09-25.75 0.76 
 c.5096G>A p.Arg1699Gln R1699Q 16 4 4.3 1.43-12.85 0.009 0 0 ND - 
 c.4258G>T p.Asp1420Tyr D1420Y 657 749 0.86 0.77 -0.96 0.005 6 8 1.01 - 0.99 
 c.7522G>A p.Gly2508Ser G2508S 0 0 ND - - 31 12 2.7 1.37-5.23 0.004 
 c.8149G>T p.Ala2717Ser A2717S 137 185 0.8 0.62-0.96 0.02 0 0 ND - - 
BRCA2 c.8187G>T p.Lys2729Asn K2729N 3 1 2.8 0.29-27.64 0.368 164 128 1.4 1.12-1.78 0.004 
 c.9104A>C p.Tyr3035Ser Y3035S 18 7 2.5 1.05-6.05 0.038 3 0 ND - - 
 c.9292T>C p.Tyr3098His Y3098H 14 20 0.7 0.35-1.38 0.304 0 0 ND - - 
a Nucleotide numbering in the reference sequences of BRCA1: NM_007294.3 ; BRCA2: NM_000059.3 
b: Adjusted for 6 European ancestry principal components 
c: Adjusted for 2 Asian ancestry principal components 
OR : odds ratio 
CI: Confidence interval 
ND: Not determined 
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Table 2. Summary of functional effects of each BRCA2 variant measured by four independent assay 
Variants Odds ratio V-C8 HDR assay Protein-DNA binding ES cells HDR assay PARP inhibitor response Overall impact
  Fold-change +/- SE % protein complexes at 20nM Relative HR +/- SE % survival at 125nM +/- SE
Wildtype N/A 5.00 17.47+/-0.01 1.00 105+/-11 (+) Wildtype 
Y31C N/A N/A N/A 0.14+/-0.06 46+/-11 (---) Deleterious 
G2508S 2.7 3.19+/-0.10 12.00+/-0.43 0.56+/-0.10 99+/-3 (-) Mild effect 
A2717S 0.8 5.08+/-0.17 12.88+/-1.89 0.85+/-0.20 90+/-14 (+) Neutral 
D2723H N/A 1.00 N/A N/A N/A (---) Deleterious 
K2729N 1.4 3.99+/-0.08 12.12+/-1.96 0.70+/-0.11 81+/-15 (-) Mild effect 
Y3035S 2.5 2.32+/-0.08 7.39+/-2.83 0.50+/-0.15 80+/-11 (--) Moderate effect
R3052W N/A 0.93+/-0.02 8.03+/-2.09 N/A N/A (---) Deleterious 
Y3098H 0.7 4.98+/0.09 N/A N/A N/A (+) Neutral 
SE: standard error of the mean; N/A: not applicable 
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FIGURE LEGENDS 
 
Figure 1. BRCA2 p.Y3035S segregates with breast cancer in high risk families. Five of the most 
informative pedigrees are shown. Upper black quadrants reflect breast cancer status. Type of 
cancer and age at diagnosis are displayed. Variant status is indicated by “Y3035S”. (+), 
mutation positive; (-), mutation negative reflects results of genetic testing. 
 
Figure 2. (A) HDR and ssDNA binding activity of BRCA2 p.Y3035S is reduced. (A) Activity of 
BRCA2 missense variants is shown as HDR fold change with standard error (SE) (of three 
independent measures of duplicates) on a scale of one to five. Solid lines represent 99.9% and 
0.1% probability of pathogenicity. (B) Representative Electrophoretic Mobility Shift Assays 
(EMSA) of DNA-protein complexes formed by mixing increasing concentrations (0, 5, 10, 20 
nM) of purified BRCA2 wildtype and mutant proteins with ssDNA. (C) Quantitation of the DNA-
protein complex formation shown in Fig. 2B. Error bars represent SE derived from at least three 
independent experiments. Statistical difference between WT and mutant BRCA2 protein-DNA 
complexes formation was determined by two-sample t-test.  **p<0.001; *p<0.05. WT, wildtype. 
 
Figure 3. HR efficiency and PARP inhibitor sensitivity of mES cells expressing hBRCA2 
variants.  (A) GFP expression from the DR-GFP reporter was analyzed as a measure of HR 
activity. The percentage GFP positive cells for each variant was normalized to wildtype hBRCA2 
expressing cells. Results represent the mean of three independent experiments with two 
independent pools of BAC clones tested per variant. Error bars represent SE of three 
independent experiments. Statistical significance is indicated by “ * ”. (B) Relative cell survival 
compared to untreated cells was determined by cell count after 48hr exposure to PARP inhibitor 
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KU-0058948. Data represent the mean of three experiments using two independent pools of 
BAC clones. **p<0.001; *p<0.05. WT, wildtype. 
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